BLEPHAMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Blephamide, and what generic alternatives are available?
Blephamide is a drug marketed by Allergan and is included in two NDAs.
The generic ingredient in BLEPHAMIDE is prednisolone acetate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Additional details are available on the prednisolone acetate; sulfacetamide sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BLEPHAMIDE?
- What are the global sales for BLEPHAMIDE?
- What is Average Wholesale Price for BLEPHAMIDE?
Summary for BLEPHAMIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 1 |
Patent Applications: | 96 |
Drug Prices: | Drug price information for BLEPHAMIDE |
What excipients (inactive ingredients) are in BLEPHAMIDE? | BLEPHAMIDE excipients list |
DailyMed Link: | BLEPHAMIDE at DailyMed |
Recent Clinical Trials for BLEPHAMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Massachusetts Eye and Ear Infirmary | Phase 4 |
Joseph B. Ciolino, MD | Phase 4 |
US Patents and Regulatory Information for BLEPHAMIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | BLEPHAMIDE | prednisolone acetate; sulfacetamide sodium | SUSPENSION;OPHTHALMIC | 012813-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Allergan | BLEPHAMIDE S.O.P. | prednisolone acetate; sulfacetamide sodium | OINTMENT;OPHTHALMIC | 087748-001 | Dec 3, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |